Neurology Main > Neurophysiology Division
ln

Neurophysiology Division
Epilepsy Program
Clinical Trials

Appointments and Referrals

Faculty
- Amir Adeli, MD
- Jacquelyne Cios, MD
- Sheri Cotterman-Hart, MD, PhD
- Lucretia Long, MS, RN, CANP
- James McAuley, RPh, PhD
- Jesse Mindel, MD
Research Staff
- Janet Renner, REEGT

Contact Us

Janet Renner, REEGT
Clinical Research Manager

OSU Appointment: 1985

Background:

Board Certification: American Board of Registered
Electroneurodiagnostic Technologists Registry Number 2020

Clinical Interests:

Clinical Trials - Janet Renner, R.EEGT. - click here to expand or contract list

Vigabitrin, Protocol VGPR0098, “Clinical Experience and Use of Sabril in Patients with Partial Seizures”.

Topamax, Protocol CAPSS-116, “An Open-Label, Multicenter Trial to Evaluate the Effect of Concomitant Anti-Epileptic Drugs (AEDs) on the Tolerability of Topamax (Topiramate) in subjects with Partial Epilepsy”.

Trileptal, Protocol US-01, “Safety and Therapeutic Effect of Oxcarbazepine in Patients with Partial Seizures”. 

Cyberonics QOLIE-31 Study, “Assesment of Effect on QOLIE-31 Scores in Refractory Epilepsy:  Comparison of Patients Using VNS to Patients trying a new AED”.

Carbatrol, Protocol 433.401, “A Multicenter, Open Label, Phase IV Study to Assess the Tolerability, Safety, and Effectiveness of Switching from Carbamazepine Immediate Release and Liquid Formulations to Carbatrol Extended Release In Epilepsy Subjects within a Community Based Population”.

A Community-Based Study Comparing the Overall Usefulness of Depakote ER vs. Depakote Tablets in Subjects with New-Onset Partial Seizures

Keppra, Protocol N01030, “ A Phase IV, Open-Label, Multi-Center Community-Based Trial Studying the Safety and Efficacy of Levetiracetam as Add-on Therapy in Adult Patients with Treatment-Resistant, Partial-Onset Epilepsy”.

Pregabalin, Protocol 1008-008, “Pregabalin Open-Label, Follow-on, Safety Trial in Patients with Refractory Partial Epilepsy.”

Pregabalin, Protocol 1008-010, “Pregabalin Open-Label Add-On Trial: An Open-Label, Multicenter, Follow-On Study to Determine the Long-term safety and Efficacy in Patients with Refractory Complex Partial or Secondarily Generalized Seizures”.

Pregabalin, Protocol 1008-035, “Pregabalin BID Open-Label Add-On Trial: An Open-Label, Multicenter, Follow-On Study to Determine Long-term Safety and Efficacy in Patients with Partial Seizures”.

A0081047 -  A double-Blind, Randomized, Multicenter Efficacy and Safety Study of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures

SPM 927, Protocol SP667, “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM927 (200 mg/day, 400 mg/day, 600 mg/day) as adjunctive Therapy in Subjects with Partial Seizures with or without secondary Generalization”.

SPM 927, Protocol SP615, “An Open-label Extension Trial to Determine Tolerability and Efficacy of Long-Term Oral SPM 927 as Adjunctive Therapy in Patients with Partial Seizures”.

SP754  A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of SPM 927 (400 and 600 mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without Secondary Generalization

SP756  An Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral SPM 927 in Patients with Partial Seizures.

SP902:  A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-onset Seizures

SP904:  A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures

SP925, A Multicenter, Open-label Trial to Assess the Safety and Tolerability of a Single Intravenous Loading Dose of Lacosamide Followed by Oral Lacosamide Maintenance as Adjunctive Therapy in Subjects with Partial-onset Seizures

SP926, A Multicenter, Open-label Extension Trial to Assess the Long-term Safety and Tolerability of Lacosamide as Adjunctive Therapy in Subjects with Partial-onset Seizures

LAM40117   A MultiCenter Open-Label, Pilot Study of Lamotrigine as Adjunctive Therapy and Monotherapy in Patients with Epilepsy and Comorbid Depressive Symptoms

LAM40112  Double-blind Randomized Trial of Cognitive Effects of LAMICTAL (lamotrigine) versus Topiramate in Epilepsy

LAM40124  An Assessment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy
A Community-Based Study Comparing the Overall Usefulness of Depakote ER vs. Depakote Tablets in Subjects with New-Onset Partial Seizures

LAM100034: A Multicenter, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive  Therapy in Subjects with Partial Seizures

LAM100036: A Multicenter, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive  Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

LAM30055: A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures

LEP105974:  A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effects of Lamotrigine Extended-Release Tablets on Comorbid Depressive Symptoms in Subjects with Epilepsy

LEP105972: A Multi-Center, Double-Blind, Historical Control, Randomized Conversion to Monotherapy Study with Keppra XR for Treatment of Partial Onset Seizures

IVAX Research: Efficacy and Safety of Talampanel as Adjunctive Therapy in Patients with Partial Seizures:  A Phase II Clinical Trial

IVAX Research: Talampanel Open-Label Adjunctive Therapy:  A Follow-On Study to Determine Long-Term Safety and Efficacy in Patients with Partial Seizures           

N01191: An open-label, exploratory, multicenter, dose-escalation study examining the efficacy, safety and tolerability of ucb 44212 ued at doses of 10 mg, 20 mg, 40 mg, and 80 mg b.i.d. (total daily dose of 20 to 160 mg) in adult subjects (18-65 years) with refractory epilepsy suffering from partial onset seizures (whether or not secondarily generalized) and treated with 1,2, or 3 approved antiepileptic drugs.

N01192: An open-label, exploratory, multicenter, dose-escalation study examining the efficacy, safety and tolerability of ucb 44212 ued at doses of 10 mg, 20 mg, 40 mg, and 80 mg b.i.d. (total daily dose of 20 to 160 mg) in adult subjects (18-65 years) with refractory epilepsy suffering from partial onset seizures who are currently receiving levetiracetam (LEV) but are still experiencing seizures.

N01193: A multicenter, double-blind, randomized, placebo-controlled, 4 parallel groups, dose-ranging trial evaluating the efficacy and safety of brivaracetam used as adjuctive treatment at doses of 5, 20, and 50 mg/day in b.i.d. administration (oral tablets of 2.5 or 10 mg) for a maximum of 7 weeks in subjects from 16 to 65 years with refractory epilepsy suffering from partial onset seizures whether or secondarily generalized.

N01199: An open-label multicenter, follow-up trial to evaluate long-tern safety and efficacy of brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 100 mg/day in subjects aged 16 years or older suffering from epilepsy.

N01253: An international, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (> 16 to 70 years old) with Partial Onset Seizures

N01280: A multi-center, double-blind, historical control, randomized conversion to monotherapy study with Keppra XR for treatment of partial onset seizures

N01281: An open-label, long-term follow-up study with Keppra XR for treatment of partial-onset seizures

333369-EPY-2003/2006:  A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Refractory Partial Seizures

333369-EPY-3001/3004:  A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-Label Extension Study

Protocol 333369-EPY-1010/1026: “Open-Label, Drug-Drug Interaction Study Between RWJ-333369 and Phenytoin Following Multiple Oral Administrations in Subjects with Epilepsy, With a Long-Term Open-Label Extension Study"

University of Florida: Neurodevelopmental Effects of Antiepileptic Drugs

E2007-A0001-206: A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E20007 Given as Adjunctive Therapy in Patients with Refractory Partial Seizures

E2007-A0001-207:  A 14-Month Open-label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 as an Adjunctive Therapy in Patients with Refractory Partial Seizures

E2080-A001-301: A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures

E2080-A001-302: An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures

K826-05-3001: A Phase 3, Randomized, Double-Blind, Parallel, Placebo-Controlled, Multicenter Study, with Optional Open-Label Continuation, of the Efficacy and Safety of Vanquix™ Auto-Injector (Diazepam Injection)for the Management of Selected, Refractory, Patients with Epilepsy who Require Intermittent Medical Intervention to Control Episodes of Acute Repetitive Seizures

1042-0600:A double-blind, randomized, placebo controlled study to evaluate the safety, tolerability, and efficacy of ganaxalone as add-on therapy in adult subjects with epilepsy consisting of uncontrolled partial-onset seizures

1042-0601: An open-label extension study to evaluate the safety, tolerability, and efficacy of ganaxalone as add-on therapy in adult patients with epilepsy consisting of uncontrolled partial-onset seizures

Presentations

"Seizure Classification and EEG Correlates", The Ohio State University 1st Annual Epilepsy Symposium.  Columbus, OH, Autumn 1995

Publications: Pubmed.com list of recent publications by Janet Renner, R.EEGT.

Appointment Phone: (614) 293-4969

Fax: (614) 688-4060

Address:
344 McCampbell Hall
1581 Dodd Drive
Columbus, OH 43210